<DOC>
	<DOCNO>NCT02740608</DOCNO>
	<brief_summary>This study design determine reject liver viable use normothermic machine liver perfusion ( NMLP ) . It aim 1. establish suitability liver decline UK liver transplant centre monitor function NMLP machine ; , 2. transplant liver function machine satisfactory allow transplant .</brief_summary>
	<brief_title>Viability Testing Transplantation Marginal Livers</brief_title>
	<detailed_description>Deaths liver disease soar 40 per cent decade continue rise . Liver transplantation highly successful treatment end stage liver disease , fulminant hepatic failure early stage primary liver cancer . The demand donor liver transplantation greatly exceed supply approximately 20 % patient die whilst await transplantation . Normothermic machine liver perfusion ( NMLP ) novel technique develop purpose organ preservation , also find allows monitor liver graft function ex-vivo measuring bile production , whilst permit objective assessment liver biochemistry blood flow . The OrganOx metra , NMLP device use , CE mark currently license particular use liver transport use device ( CE mark currently cover ) . The device use particular site ( case University Hospitals Birmingham ) period static cold storage liver transport hospital testing device . The study population extend criterion donor liver , reject transplantation UK centre , find function perfusion transplant `` medium low-risk '' liver transplant recipient . VITTAL open label , non-randomised , prospective , single arm , 2-part trial objective : - Further validate liver viability assessment criterion - Perform phase 2 study transplant successfully resuscitate `` reject '' liver - Establish feasibility NMLP mean increase number transplantable liver . - Identify novel biomarkers indicative liver quality function In term intervention , procurement transplantation organ follow current standard care . The deviation current standard normothermic perfusion organ follow static cold storage order test ability function . This study base result 5-case pilot series transplant low-risk recipient organ reject transplantation show function normothermic machine perfusion device . This work currently process publish . The main risk would transplantation non-functioning graft ( result case primary non-function could result re-transplantation patient death . ) Based pre-clinical research clinical pilot series believe criterion identify indicate organ function stringent significantly reduce risk .</detailed_description>
	<criteria>Inclusion Criteria ( donor graft ) : 1 . Liver donor primary accept intention clinical transplantation 2 . Liver graft reject UK transplant centre via normal fasttrack sequence 3 . Cold ischaemic time le 16 hour DBD 10 hour DCD graft 4 . One follow parameter capture objectivity liver highrisk status Donor risk index great 2.0 Graft steatosis great 30 % BAR score great 9 ; Donor warm ischaemic time great 30 minute Anticipated cold ischaemic time great 12 hour DBD 8 hour DCD liver graft Suboptimal liver graft perfusion document photo macroscopic appearance Liver transaminases ( ALT AST ) 1000 IU/mL Exclusion Criteria ( donor graft ) : 1 . Grafts patient active Hepatitis B , C HIV infection 2 . Livers cirrhotic macroscopic appearance 3 . Livers advance fibrosis 4 . DCD graft donor warm ischaemic time ( systolic blood pressure le 50mmHg aortic perfusion ) 60 minute 5 . Excessive cold ischaemic time ( DBD 16 hour / DCD 10 hour ) Criteria transplantation : 1 . Evidence bile production 2 . Perfusate lactate level less equal 2.5 mmol/L 3. pH great 7.30 4 . Metabolism glucose 5 . Stable arterial flow 150 mL/ minute portal flow 500 mL/minute 6 . Homogeneous graft perfusion soft consistency parenchyma Inclusion Criteria ( subject ) : 1 . Adult primary liver transplant recipient 2 . Patient list electively transplantation 3 . Low moderate transplant risk candidate , suitable marginal graft , assess UHB liver transplant list MDT meeting ( usually candidate low UKELD score , without cardiovascular comorbidities , good functional nutrition status , patent portal vein history previous major upper abdominal surgery , e.g . patient transplant liver cancer ) Exclusion Criteria ( subject ) : Subjects meet follow exclusion criterion exclude participate VITTAL trial : 1 . Highrisk patient recipient suitable marginal graft ( mainly patient high UKELD score ( &gt; 62 per NHSBT LAG criterion graft share highrisks recipient North East UK [ http : //www.odt.nhs.uk/pdf/advisory ... /Liver_National_Allocation_Scheme.pdf ] ) , cardiovascular comorbidities renal insufficiency , poor nutrition performance status history major upper abdominal surgery , e.g . patient list liver retransplantation ) 2 . Patients complete portal vein thrombosis diagnose prior transplantation 3 . Liver retransplantation 4 . Patients fulminant hepatic failure 5 . Patients undergo transplantation one organ 6 . Contraindication magnetic resonance imaging ( i.e . pacemaker fit )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>